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The obesity epidemic has led to increased use of Roux-en-Y gastric bypass (RYGB). These patients have an increased incidence of pancreaticobiliary diseases yet standard ERCP is not possible due to surgically altered gastroduodenal anatomy. Laparoscopic-ERCP (LA-ERCP) has been proposed as an option but supporting data are derived from single center small case-series.
Therefore, we conducted a large multicenter study to evaluate the feasibility, safety, and outcomes of LA-ERCP.
Methods
This is retrospective cohort study of adult patients with RYGB who underwent LA-ERCP in 34 centers. Data on demographics, indications, procedure success, and adverse events were collected. Procedure success was defined when all of the following were achieved: reaching the papilla, cannulating the desired duct and providing endoscopic therapy as clinically indicated.
Results
A total of 579 patients (median age 51, 84% women) were included. Indication for LA-ERCP was biliary in 89%, pancreatic in 8%, and both in 3%. Procedure success was achieved in 98%.
Median total procedure time was 152 minutes (IQR 109-210) with median ERCP time 40 minutes (IQR 28-56). Median hospital stay was 2 days (IQR 1-3). Adverse events were 18% (laparoscopy-related 10%, ERCP-related 7%, both 1%) with the clear majority (92%) classified as mild/moderate whereas 8% were severe and 1 death occurred.
Conclusion
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Our large multicenter study indicates that LA-ERCP in patients with RYGB is feasible with a high procedure success rate comparable with that of standard ERCP in patients with normal anatomy. ERCP-related adverse events rate is comparable with conventional ERCP, but the overall adverse event rate was higher due to the added laparoscopy-related events.
Background
The current obesity epidemic has consequently led to an increase in bariatric surgery, with more than 100,000 procedures per year being performed in the United States alone 1 . In recent years, the most common bariatric surgery has been and continues to be Roux-en-Y gastric bypass (RYGB) 1,2 . This operation excludes most of the stomach (ie, remnant stomach) and all of the duodenum making conventional duodenoscopy and per-oral ERCP impossible. Importantly, ERCP is commonly indicated in RYGB patients due to an increased risk of choledocholithiasis and gallstone pancreatitis especially in the setting of rapid weight loss after bariatric surgery 3, 4 . Furthermore, several reports have shown increased rate of pancreaticobiliary malignancies in obese patients 5, 6 .
Various alternative ERCP approaches for patients with RYGB have been described. Per-oral deep enteroscopy techniques such as single-balloon, double-balloon and spiral enteroscopy are minimally invasive but therapeutic success is far lower compared with standard ERCP. This inferiority is due to the inability to reach the papilla secondary to the surgically altered gastroduodenal anatomy, failure to cannulate the desired duct, or failure to provide therapy due M A N U S C R I P T
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to the change of orientation of the papilla, difficult endoscope position, use of forward optics, lack of elevator, small therapeutic channel and/or limited availability of devices [7] [8] [9] [10] [11] [12] [13] .
Percutaneous access to the gastric remnant by interventional radiology has been described, but has not gained wide acceptance because it is impractical for urgent cases due to the requirement of serial dilation and track maturation [14] [15] [16] . This is further hindered by the inconvenience of needing a gastrostomy tube (G-tube) and the technical difficulties related to the inability to distend the stomach remnant with air 6, 17 . EUS-guided transgastric ERCP is another innovative approach 18, 19 . However, this methodology has several cited limitations most prominently is the potential for creating a permanent gastro-gastric fistula that compromises the integrity of the RYGB and the need for 2 stage procedure [20] [21] [22] .
Laparoscopy-assisted ERCP (LA-ERCP) is accomplished by placing trocar in the remnant stomach under laparoscopic guidance followed by insertion of the conventional duodenoscope through the trocar to reach the ampulla of Vater. ERCP is then carried out in a standard fashion.
The main appeal of LA-ERCP is that it is a single-stage procedure and affords the use of standard ERCP equipment including doudenoscope and accessories. This anticipates a very high procedural success, similar to patients with normal upper GI tract anatomy. LA-ERCP was first described in 2002 and since then, only a few small single-center case series have been published showing high success rates and low adverse events rates 6, 7, [23] [24] [25] . Despite these early encouraging results, the role of LA-ERCP has not been well defined due to a lack of high quality data.
Therefore, the aim of this study was to evaluate a large multicenter cohort to assess the feasibility, safety and outcomes of LA-ERCP in patients with RYGB.
Methods
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
This is a retrospective multicenter cohort study that included adult patients with RYGB who underwent LA-ERCP between 2005 and 2016. The study was approved by the institutional review board (IRB) of each of the participating centers, with the University of Florida serving as the central coordinating center. All authors had access to the study data and reviewed and approved the final manuscript.
Procedure
Procedure informed consents for both ERCP and Laparoscopy were obtained from all patients.
All procedures were performed in the operating room or designated sterile endoscopy room by both a laparoscopy and endoscopy teams with the patient in supine position under general anesthesia. Percutaneous access with trocar to the remnant stomach was established laparoscopically. Therapeutic duodenoscope was subsequently inserted through the indwelling trocar into the remnant stomach and advanced into the duodenum. ERCP was then carried out in a standard fashion using a conventional duodenoscope and accessories. The gastrostomy and the percutaneous tracts were closed surgically at the end of the procedure or a G-tube is left in place in cases where ERCP might be needed again in the future. All patients were inpatients or were admitted for observation postoperatively.
Data collection
A standardized data entry form was distributed through secured email across all the centers to collect information on baseline characteristics, intra-procedural and follow-up data. Baseline 
Results
Thirty-four centers participated in this study (31 from the United States, 2 from Brazil, and 1 from Canada, Table 1 ). A total of 579 patients with RYGB (84% women) with median age of 51 (interquartile range (IQR) 43-61) underwent LA-ERCP during the study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) ( Table 2 ). The number of procedures performed per year increased noticeably after 2011 reflecting increased adoption of this approach (Figure 1 ).
Indications for LA-ERCP are outlined in Table 2 . Main indications for procedures were: biliary in 89%, pancreatic in 8% and both biliary and pancreatic in 3% of the cases. Approximately half (47%) of all biliary interventions were due to choledocholithiasis whereas acute pancreatitis (93%) was the most common indication for pancreatic intervention. The most common therapeutic interventions were biliary sphincterotomy (96%), stone extraction (44%), and pancreatic stent placement (15%), (Table 3) . Eleven patients (26%) among those with pancreatic pre-operative indication had stone extraction. Concomitant laparoscopic cholecystectomy was performed in 21% of the cases and gastric tube was left in place in 17% of the cases for possible subsequent intervention(s).
Overall procedure success was achieved in 98%. The papilla was successful reached in 99% and cannulating the desired duct in 98% of the cases (bile duct cannulation 99%, pancreatic duct cannulation 91%). Success rate in performing the desired intervention was 98% (biliary 99%, Adverse events were reported in 106 out of 579 (18%) patients. Laparoscopy-related adverse events were reported in 10% whereas ERCP-related adverse events were reported in 7% of the patients. One percent of the patients had adverse events related to both laparoscopy and ERCP.
The most common laparoscopy associated adverse event was postoperative infections in 24 out of 579 (4.1%), whereas the most common ERCP-related adverse event was acute pancreatitis in 42 out of 579 (7.4%), ( Table 4 ). The rate of pancreatitis varied by the LA-ERCP main indication, among those who had the procedure for biliary indications was 7%. Compared with the rate among those with pancreatic and both (biliary and pancreatic) indications, which was 11% and 13%, respectively (p=0.3). Regarding the severity of these events, 60% were classified as mild and 31% as moderate whereas 8% were classified as severe and one death was reported.
In 5% of the cases ERCP was carried out after conversion to open laparotomy to gain access to the remnant stomach.
We explored the factors associated with laparoscopic versus ERCP-related events by series of univariate analysis as presented in Table 5 . Longer duration since RYGB showed a trend towards higher laparoscopy-related events (<3 years had 8%, 3-6 years had 10%, 6-9 years had 10%, and those with >10 years since RYGB had 16%, p=0.516). Conversion to open laparotomy was associated with significant increase in the risk of laparoscopy-related events (24% versus 10%, p=0.045). Leaving a G-tube in place at the end of the procedure was also significantly associate with increased risk of adverse events (17% versus 9%, p=0.036). These factors (years since RYGB, conversion to open, and leaving G-tube) did not affect the ERCP-related adverse events.
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Most of the patients (85%) received peri-operative antibiotics. Antibiotics use was associated with a numerically higher overall adverse events rate (19% versus 13%, p = 0.198), a numerically higher rate of any infectious adverse events (6.2% versus 3.4%, p = 0.451), and a numerically higher rate of G tube site infection (1.4 % versus 0%, p = 0.603).
Discussion
The feasibility of LA-ERCP has been reported from a few single-center case series, with reported success rate ranging from 80% to 100% and adverse events rate ranging from 0% to 30% 6,7,23-25,27-32 . These reports are limited by small sample size and heterogeneous definitions of procedure success and adverse events. In our large multicenter study, LA-ERCP in patients with RYGB was highly successful with success rates comparable to standard ERCP in patients with normal upper GI tract anatomy 33 . In our study, the overall success rates in reaching the papilla, cannulating the desired duct and performing the indicated therapeutic intervention was 98%.
Furthermore, we also demonstrated that LA-ERCP is feasible and efficient. Our total procedure time (laparoscopy + ERCP) was 152 minutes with median length of hospital stay of 2 days.
In our series, ERCP-related adverse events rate appear comparable with conventional ERCP, although the overall rate of adverse events was higher due to the addition of those attributed to laparoscopy 33 . Importantly, the clear majority (92%) of the reported adverse events were classified as mild to moderate. Nevertheless, serious adverse events were seen including viscus perforation in 5/579 (0.8%) cases. Two patients had sphincterotomy-related duodenal perforations, whereas the rest were laparoscopy-related (2 colonic and 1 gastric remnant perforation [trocar perforated the posterior stomach wall]). In one of the perforation cases, multi-organ failure occurred and the patient died after a prolonged hospitalization.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Placing an indwelling G-tube and conversion to open laparotomy were factors significantly associated with higher laparoscopy-related adverse events. Patients who had G tube left had higher overall laparoscopy associated adverse events (17% versus 9%, p =0.03). This was attributed to G tube site infection (6%), gastric entry-site leak (4%), and all-causes laparoscopyassociated bleeding (7%). Of note, all patients who had G tube site infection did receive perioperative antibiotics as part of their care. Based on these data, it seems reasonable to avoid Gtube insertion unless a repeat procedure is definitely indicated, ( Table 5 ).
Most of the patients included in our series (85%) received periprocedural antibiotics. There was no statistically significant difference in infection rate between those who received antibiotics versus those who did not. Nevertheless, we cannot exclude any difference based on our findings due to the very low rate of infections and low statistical power to answer this question.
Therefore, our data cannot provide definitive guidance for or against the use of perioperative antibiotics.
Our findings are comparable with the recently published systematic review of 26 studies by Banerjee et al that included 509 laparoscopic and open trans-gastric ERCP cases 34 . The success rate in reaching the papilla, cannulation, and performing therapeutic intervention were 98.9%, 98.5%, and 98.5%, respectively. Adverse events were reported in 14% of cases, with lower G tube site infection (3.7%) and laparoscopy-associated bleeding (0.9%), and no reported death compared with our findings 34 .
It is noteworthy that EUS-guided transgastric ERCP is currently an evolving and promising approach that involves deploying lumen-apposing metal stent (LAMS) through the newly formed gastro-gastric fistula 18 . Then the intended ERCP could be performed by passing the endoscope into the remnant stomach through the LAMS [18] [19] [20] . This approach can potentially offer great M A N U S C R I P T
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advantages including the lack of need for surgical team, minimal invasiveness, and the higher success rate and shorter operative time compared with enteroscopy assisted ERCP. However, this methodology has several cited limitations most prominently the potential for creating a permanent fistula that compromises the integrity of the RYGB [20] [21] [22] , high LAMS dislodgement rate (19%), and the need for multiple sessions in two-thirds of the patients to allow time for track maturation 35 . Nonetheless, this is a promising approach and direct comparison with LA-ERCP is warranted in future research.
The main strengths of our study include (1) Nonetheless, there are several challenging aspects of LA-ERCP that must be addressed before adoption of this procedure by a medical center. The center must have expertise in bariatric surgery as well as advanced endoscopy. Secondly, maintaining sterility, the lay out of the OR, and its equipment are different from what the endoscopy team is accustomed to in the usual endoscopy suites 25 . Thus, a special protocol has to be devised and taught to the endoscopy team 25 . In addition, a great deal of schedule coordination is required to ensure that the endoscopist and the surgeon along with their teams are present in the OR at the same time to avoid delays 25 .
At the University of Florida and The Cleveland Clinic, the LA-ERCPs are typically scheduled as the first cases of the day to ensure that the 2 teams are available and there would be no interference with the rest of the OR and endoscopy schedules.
Our study has the typical limitations inherent to retrospective design related to potential for patient selection bias, and measurement bias particularly the under-reporting of adverse events.
We anticipate that underreporting was minimized in our cohort because all of our patients were inpatients or were admitted to the hospital after surgery, making detection and reporting of adverse events more likely. In addition, for clarity of reporting we divided adverse events into ERCP or laparoscopy-related categories. Such a distinction may be straightforward for most adverse events such as post-ERCP pancreatitis but could be arbitrary for others such as cardiovascular compromise. Nevertheless, the reported overall adverse event rate should provide an accurate estimate to use as a guide for physicians and patients.
Our large multicenter study indicates that LA-ERCP in patients with RYGB is highly successful, with success rates comparable to standard ERCP in patients with normal upper GI tract anatomy. M A N U S C R I P T 
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